West C P, Lumsden M A, Lawson S, Williamson J, Baird D T
Fertil Steril. 1987 Jul;48(1):45-51. doi: 10.1016/s0015-0282(16)59288-7.
Thirteen premenopausal women with uterine fibroids were treated for a maximum of 6 months with a long-acting agonist of luteinizing hormone-releasing hormone (LH-RH), goserelin (Zoladex depot, ICI Pharmaceuticals, Macclesfield, UK) 3.6 mg, administered subcutaneously every 28 days. A 55% reduction (range, 38% to 84%) in uterine volume assessed by ultrasound was obtained. The greatest reduction (30%) was apparent within the first treatment cycle regardless of whether treatment was started in the early follicular or the luteal phase. Fibroid regression was inversely correlated with urinary estrogen concentration. Treatment was well tolerated and only one subject withdrew from the study before its scheduled completion. Following cessation of therapy, ovulatory menstruation returned within 3 months in the majority of the subjects, but this was accompanied by a rapid regrowth of the fibroids. This medical approach to the management of fibroids merits further investigation but as yet cannot be regarded as an alternative to surgery.
13名患有子宫肌瘤的绝经前女性接受了为期最长6个月的治疗，使用的是促黄体生成素释放激素（LH-RH）长效激动剂戈舍瑞林（诺雷德缓释植入剂，英国麦克尔斯菲尔德ICI制药公司生产），剂量为3.6毫克，每28天皮下注射一次。通过超声评估，子宫体积减少了55%（范围为38%至84%）。无论治疗是在卵泡早期还是黄体期开始，最大减少量（30%）在第一个治疗周期内就很明显。肌瘤缩小与尿雌激素浓度呈负相关。治疗耐受性良好，只有一名受试者在研究预定完成前退出。治疗停止后，大多数受试者在3个月内恢复排卵性月经，但与此同时肌瘤迅速复发。这种治疗肌瘤问题的医学方法值得进一步研究，但目前还不能被视为手术的替代方法。
